Alan M. Garber
Known title: DirectorCIK: 0001312907
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.
Transaction History
| VRTX | ▲ Buy | Grant | 472 | $0 | 5/1/2026 | View on chart |
| VRTX | ▲ Buy | Grant | 398 | $0 | 5/1/2025 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 23,491 | $460K | 3/21/2024 | View on chart |
| EXEL | ▼ Sell | Open Market | 19,205 | $461K | 3/21/2024 | View on chart |
| VRTX | ▲ Buy | Grant | 584 | $0 | 5/1/2023 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 40,000 | $252K | 2/21/2023 | View on chart |
| EXEL | ▼ Sell | Open Market | 40,000 | $700K | 2/21/2023 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 40,000 | $125K | 3/1/2022 | View on chart |
| EXEL | ▼ Sell | Open Market | 21,301 | $447K | 3/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion
Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.
Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.